$47.69
-0.60%Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Chairman, President & Chief Executive Officer
Compensation
$5,336,644
Executive Vice President & Chief Financial Officer
Compensation
$2,340,961
Executive Vice President & Chief Financial Officer
Executive Vice President & Group President of Cardiology
Compensation
$2,196,309
Executive Vice President & President of Peripheral Interventions
Compensation
$1,499,130
Executive Vice President and Group President of MedSurg & Asia Pacific
Compensation
$1,705,126
Executive Vice President of Global Operations
General Manager of Global Sales & Marketing
Senior Vice President & Chief Human Resources Officer
Senior Vice President and Chief Information & Digital Officer
Senior Vice President of Investor Relations
Senior Vice President, General Counsel & Corporate Secretary
During the last 12 months, insiders have purchased $554K and sold $33.38M worth of BSX shares, resulting in $32.83M of net selling activity.
9.8K
554.00K
0
0.00
+554K
+$554K
0
0.00
1.2K
112.87K
-113K
-$113K
0
0.00
114.3K
11.36M
-11.4M
-$11.36M
0
0.00
208.8K
21.91M
-21.9M
-$21.91M
Habiger David C
Director
$251K
Ludwig Edward J
Director
$203K
Pegus Cheryl
Director
$100K
Fitzgerald Joseph Michael
Officer: Evp & Group Pres, Cardiology
$26.39M
Butcher Arthur C
Officer: Evp& Grp Pres, Medsurg & Apac
$3.57M
Zane Ellen M
Director
$2.57M
Ludwig Edward J
Director
$424K
Fujimori Yoshiaki
Director
$310K
Strong bearish signal with $32.83M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
BSX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 19, 2025 | March 19, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 20, 2024 | March 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | March 22, 2023 | May 04, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | March 23, 2022 | May 05, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 24, 2021 | May 06, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 25, 2020 | May 07, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 27, 2019 | May 09, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 28, 2018 | May 10, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 28, 2017 | May 09, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.